| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
AD and its comorbidities: An obstacle to develop a clinically efficient treatment?
|
Baker, J.
|
|
|
178 |
5 |
p. 450-459
|
artikel
|
| 2 |
Biomarkers and diagnosis of dementia with Lewy bodies including prodromal: Practical aspects
|
Blanc, F.
|
|
|
178 |
5 |
p. 472-483
|
artikel
|
| 3 |
Contents
|
|
|
|
178 |
5 |
p. iv-v
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
178 |
5 |
p. i
|
artikel
|
| 5 |
Foreword
|
Azulay, J.-P.
|
|
|
178 |
5 |
p. 405
|
artikel
|
| 6 |
How can we define the presymptomatic C9orf72 disease in 2022? An overview on the current definitions of preclinical and prodromal phases
|
Saracino, D.
|
|
|
178 |
5 |
p. 426-436
|
artikel
|
| 7 |
How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?
|
Chételat, G.
|
|
|
178 |
5 |
p. 490-497
|
artikel
|
| 8 |
Molecular imaging in Parkinsonism: The essential for clinical practice and future perspectives
|
Horowitz, T.
|
|
|
178 |
5 |
p. 484-489
|
artikel
|
| 9 |
Neurodegenerative disorders: Are we wrong?
|
Agid, Y.
|
|
|
178 |
5 |
p. 407-413
|
artikel
|
| 10 |
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders
|
Lopez-Cuina, M.
|
|
|
178 |
5 |
p. 460-471
|
artikel
|
| 11 |
Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?
|
Villain, N.
|
|
|
178 |
5 |
p. 437-440
|
artikel
|
| 12 |
What contribution can genetics make to predict the risk of Alzheimer's disease?
|
Schramm, C.
|
|
|
178 |
5 |
p. 414-421
|
artikel
|
| 13 |
What did we learn from neural grafts in Huntington disease?
|
Bachoud-Lévi, A.-C.
|
|
|
178 |
5 |
p. 441-449
|
artikel
|
| 14 |
When does Huntington disease begin?
|
Durr, A.
|
|
|
178 |
5 |
p. 422-425
|
artikel
|
Tijdschrift beschrijving